Neurotrope (NTRP) Stock Price, News & Analysis

Company Overview

Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.

Key Stats

• Today's Range: $6.63 to $7.45
• 50-Day Range: $0.92 to $1.05
• 52-Week Range: $0.68 to $3.85
• Volume: 27,026 shs
• Average Volume: 34,309 shs
• Market Capitalization: $10.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Neurotrope Stock Analysis - MarketRank™

Neurotrope scored higher than 8% of companies evaluated by MarketBeat, and ranked 284th out of 293 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Neurotrope.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neurotrope are expected to grow in the coming year, from ($0.91) to ($0.10) per share.

Price to Book Value per Share Ratio

Neurotrope has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.43% of the float of Neurotrope has been sold short.

Short Interest Ratio / Days to Cover

Neurotrope has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neurotrope has recently decreased by 18.72%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurotrope does not currently pay a dividend.

Dividend Growth

Neurotrope does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.43% of the float of Neurotrope has been sold short.

Short Interest Ratio / Days to Cover

Neurotrope has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neurotrope has recently decreased by 18.72%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NTRP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neurotrope insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.00% of the stock of Neurotrope is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 3.81% of the stock of Neurotrope is held by institutions.

NTRP Stock Analysis - Frequently Asked Questions

How were Neurotrope's earnings last quarter?

Neurotrope, Inc. (NASDAQ:NTRP) announced its earnings results on Tuesday, January, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by $0.01.

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Bristol-Myers Squibb (BMY), Intel (INTC), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

• Last Earnings: 1/14/2025
• Today: 1/22/2025
• Fiscal Year End: 2/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Discretionary
• Industry: Transportation services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NTRP
• CUSIP: N/A
• CIK: 1513856
• Web: www.neurotropebioscience.com
• Phone: 973-242-0005
• Fax: 505-424-3174
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: -1,320.29%
• Return on Equity: -806.36%
• Return on Assets: -112.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.24
• Quick Ratio: 0.24

Sales & Book Value

• Annual Sales: $630,000.00
• Price / Sales: 17.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.34 per share
• Price / Book: 2.05

Miscellaneous

• Outstanding Shares: 1,590,000
• Free Float: 1,386,000
• Market Cap: $10.89 million
• Optionable: No Data
• Beta: 1.67